Cipla partners with Boehringer Ingelheim India to co-market three new oral anti-diabetic drugs - Business Standard 30-Jun-2020

Cipla partners with Boehringer Ingelheim India to co-market three new oral anti-diabetic drugs - Business Standard

Empagliflozin is approved for glucose-control in patients with type-2 diabetes; it is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease. The Empagliflozin +

More...